 Diagnosis Number of pts. Prevalence Low-grade dysplasia LGD 101 7.3 High-grade dysplasia HGD 42 3 Esophageal adenocarcinoma 91 6.7 Incidence and progression to low-grade dysplasia, high-grade dysplasia and esophageal adenocarcinoma. 1376 patients were enrolled in the prevalence phase of the study. To date, 618 patients 95 Caucasians, 14 Females have had follow-up endoscopic procedures to examine the incidence of dysplasiacancer. They have been followed for a total of 2546 patient-years; mean follow up 4.12 patient-years range: 1-22.5 yrs. Twelve patients developed cancer during follow up for a cancer incidence of 1 in 212 patient-years of follow up or 0.5 per year. The mean time to development of cancer was 5.3 yrs range: 2.4-11.2 yrs. Of interest, 7 of 12 patients had high-grade dysplasia before cancer development while 2 had only low-grade dysplasia; 3 developed cancer from BE without dysplasia documented at any point. 22 patients developed high-grade dysplasia during follow up for an estimate of high-grade dysplasia incidence of 1 in 116 patient-years of follow up or 0.9 per year. The mean time to high-grade dysplasia development was 3.8 yrs range: 1.2-7.9 yrs. 11 of 22 patients developed high-grade dysplasia from BE without documented dysplasia, whereas the remaining 11 went from low-grade dysplasia to high-grade dysplasia. 